Airmid   Phone: (650) 368 6983
info@airmid.com
 
Target Portfolio >>AIRMIDs Therapeutics

Two of AIRMID’s drug candidates
  • Most potent and selective oral and topical Kv1.3 blocker known (KD = 2nM).
  • Excellent safety profile.
  • Patent protected.
  • Derivative of a natural compound from the plant, Ruta graveolens.
   
  • Highly potent and most selective Kv1.3 blocker known (KD = 70pM).
  • Excellent safety profile.
  • Injectable.
  • Patent protected.
  • Derivative of a natural compound from the sea anemone, Stichodactyla helianthus.
By starting from natural sources of potential autoimmune drugs and applying creative methods of derivatization, AIRMID’s founders have succeeded in developing therapeutically promising Kv1.3 blockers even as several large pharmaceutical companies have failed.
 
 
February 2011
February 2011 AIRMID partners with Circassia to develop topical PAP-1
January 2010
Joe Sum joins AIRMID Board of Directors
July 2009
AIRMID partners with Kineta
to develop ShK peptides

more...
Home | Autoimmune disease | Multiple sclerosis | Type 1 diabetes mellitus | Kv1.3 Potassium Channel | PAP-1 | ShK
Effector memory T cells | Contact | Sitemap
Copyrights © 2007, www.airmid.com